Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT05720559
PHASE2

Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

Sponsor: Liaoning Cancer Hospital & Institute

View on ClinicalTrials.gov

Summary

In this study, the Quintuple method was applied for early intervention of prehepatic CTC-positive bowel cancer patients without dominant liver metastasis, aiming to explore the blocking effect of the Quintuple method on the metachronous liver metastases of colorectal cancer. A one-arm randomized clinical trial was conducted, and the patients were grouped according to their treatment methods. The patients with metachronous liver metastases were used as the end point of the experiment to evaluate the blocking effect of quintuple therapy.

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2023-03-01

Completion Date

2026-09-01

Last Updated

2023-02-09

Healthy Volunteers

No

Interventions

DRUG

Oxaliplatin

Oxaliplatin via intravenous drip on d1 at a dose of 130mg/m2 × patient 's body surface area

DRUG

S1

Orally on d2-d15 at 20 mg three times daily

DRUG

Cetuximab

Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.

DRUG

Metronidazole

Metronidazole 0.4g/time, qd

DRUG

Vitamin A

Vitamin A 25,000 units/time, qd

DRUG

Folic acid

Folic acid 0.4 mg/time, qd

DRUG

Capecitabine

Capecitabine via orally on d2-d15 two times daily at a dose of 1000mg/m2 × patient 's body surface area.